Healthcare Scan
Healthcare Scan
Healthcare in systemic distribution — SYK and MDT hit new multi-month lows, UNH in confirmed death cross with -44.6% 1yr loss, while MRNA and JNJ provide isolated pockets of relative strength in an otherwise sector-wide selloff.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🔴 BEARISH / SECTOR-WIDE SELLOFF — Medical devices, managed care, and life science tools all breaking down; only select biotech/pharma holding |
| Leaders | MRNA ($51.39, RSI 51, +47.3% 3M), JNJ ($235.90, RSI 43, +14.4% 3M), BIIB ($182.13, RSI 45, +4.3% 3M) |
| Laggards | MDT ($86.32, RSI 25↓), SYK ($335.30, RSI 32↓, -11.8% 30D), UNH ($278.27, -44.6% 1yr) |
Price Table (2026-03-20)
| Stock | Price | RSI | vs SMA20 | 7D% | 30D% | 3M% | Trend | Signal |
|---|---|---|---|---|---|---|---|---|
| MDT | $86.32 | 25 ↓ | -6.3% | -0.8% | -10.9% | -11.0% | down | 🟢 Extreme Oversold |
| SYK | $335.30 | 32 ↓ | -7.8% | +0.0% | -11.8% | -5.7% | strong-down | 🟡 Approaching Oversold |
| LLY | $903.48 | 30 ↓ | -8.9% | -7.8% | -10.5% | -16.0% | weak-down | 🟢 Oversold |
| AMGN | $346.43 | 35 ↓ | -6.8% | -5.2% | -7.6% | +5.3% | weak-down | 🟡 Watch |
| GILD | $137.72 | 37 ↓ | -5.1% | -3.3% | -8.5% | +11.6% | weak-down | 🟡 Watch |
| TMO | $472.83 | 34 ↓ | -4.7% | -0.1% | -7.4% | -17.8% | down | 🟡 Watch |
| ISRG | $475.47 | 39 ↓ | -3.0% | +0.3% | -5.7% | -18.0% | strong-down | 🟡 Watch |
| DXCM | $66.82 | 42 ↓ | -4.1% | +3.5% | -8.6% | -0.9% | strong-down | 🟡 Watch |
| UNH | $278.27 | 43 ↓ | -2.0% | -0.2% | -3.3% | -13.8% | strong-down | 🔴 Broken Trend |
| VRTX | $455.65 | 44 ↓ | -3.9% | -3.4% | -4.5% | -1.0% | weak-down | 🟡 Hold |
| BIIB | $182.13 | 45 ↓ | -2.8% | -1.0% | -5.2% | +4.3% | weak-down | 🟡 Hold |
| VEEV | $184.23 | 46 ↓ | -0.3% | +1.3% | +2.2% | -17.5% | strong-down | 🟡 Watch |
| JNJ | $235.90 | 43 ↓ | -2.8% | -2.8% | -2.2% | +14.4% | strong-up | 🔒 Hold |
| MRNA | $51.39 | 51 | -3.1% | -2.8% | +3.1% | +47.3% | strong-up | 🔒 Hold |
| REGN | $733.70 | 40 ↓ | -4.2% | -1.4% | -5.9% | -5.7% | weak-down | 🟡 Watch |
Tier Analysis
Tier 1 — Extreme Oversold / Capitulation
MDT ($86.32, RSI 25): Medtronic is the cleanest oversold setup in the scan — RSI 25, -10.9% in 30 days, -11% in 3 months. Device slowdown is real, but this is a diversified medical device giant with a 5yr history of resilience. At -18.8% from 52wk high and below all SMAs, the risk/reward is shifting favorable. Needs a volume stabilization signal before entering.
LLY ($903.48, RSI 30): Eli Lilly's GLP-1 dominance (Mounjaro, Zepbound) is not in dispute — this is a macro/sector selloff dragging the best pharma franchise down. -16% in 3 months from prior euphoria levels. RSI 30 is the first meaningful oversold signal LLY has flashed in 3+ years of outperformance.
Tier 2 — Under Pressure / Watch Closely
SYK ($335.30, RSI 32, -11.8% 30D): Stryker is a quality med-tech compounder with a death cross now active. -17.2% from 52wk high. Elective surgery cycle is a macro story — if hospital spending slows, SYK feels it. Interesting below $330.
ISRG ($475.47, RSI 39, -18% 3M): Da Vinci robot monopoly is structurally intact. But -21.3% from 52wk high and death cross active. This is a quality name getting thrown out with the sector. The patience play.
TMO ($472.83, RSI 34, -17.8% 3M): Life science tools continue structural de-rating. NIH/FDA headwinds and biotech funding pressure mean the research spending cycle is soft. Below all SMAs.
UNH ($278.27, RSI 43): The managed care overhang is real — CMS rate pressure, political/regulatory uncertainty, and the company's ongoing legal/regulatory issues. Death cross confirmed, -44.6% 1yr loss. Avoid until clarity.
Tier 3 — Relative Strength / Holding
MRNA ($51.39, RSI 51, +47.3% 3M): The comeback kid. mRNA thesis partially rehabilitated after RSV/flu vaccine progress. Strong-up trend with golden cross. The run has been significant — pullback risk exists, but thesis is recovering.
JNJ ($235.90, RSI 43, +14.4% 3M): Johnson & Johnson showing best relative strength in the scan after the talc litigation resolution. Strong-up trend, golden cross active. +22.4% above SMA200. The quality large-cap defensive play in healthcare.
BIIB ($182.13, RSI 45, +4.3% 3M): Alzheimer drug (Leqembi) franchise is the optionality play. Modest positive 3M in a terrible sector. Hold.
Tier 4 — Structurally Challenged
VEEV ($184.23, RSI 46, -17.5% 3M): Veeva's cloud CRM for life sciences faces growth deceleration as biotech funding tightens. -38.9% from 52wk high. Death cross. The growth premium has been stripped; now trading on fundamentals.
DXCM ($66.82, RSI 42): CGM market leader with death cross and structural competitive pressure from Abbott's Libre. -25.7% from 52wk high.
Entry Zones
| Stock | Current | Zone | RSI | 30D% | Action | Notes |
|---|---|---|---|---|---|---|
| MDT | $86.32 | <$90 | 25 ↓ | -10.9% | ✅ Strong Buy | Device compounder at capitulation — wait for volume signal |
| LLY | $903.48 | <$900 | 30 ↓ | -10.5% | 📈 Accumulate | GLP-1 thesis intact, first real oversold signal in years |
| SYK | $335.30 | <$330 | 32 ↓ | -11.8% | 🔍 Watch | Quality med-tech, death cross caution, approaching oversold |
| ISRG | $475.47 | <$470 | 39 ↓ | -5.7% | 🔍 Watch | Monopoly robotics surgeon, needs RSI < 35 |
| JNJ | $235.90 | <$232 | 43 ↓ | -2.2% | 📈 Accumulate | Best current quality/safety in the sector |
| GILD | $137.72 | <$138 | 37 ↓ | -8.5% | 📈 Accumulate | HIV/oncology compounder, golden cross intact |
| VRTX | $455.65 | <$455 | 44 ↓ | -4.5% | 🔍 Watch | CF monopoly, moderate pullback, needs lower RSI |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| ✅ STRONG BUY | MDT | RSI 25, diversified device leader at capitulation |
| 📈 ACCUMULATE | LLY, JNJ, GILD | Quality pharma at discount; DCA approach |
| 🔒 HOLD | MRNA, JNJ | Working names, don't sell relative strength |
| 🔍 WATCH | SYK, ISRG, VRTX | Right quality, wrong RSI — patience required |
| ❌ DON'T BUY | UNH | Death cross, regulatory overhang, -44.6% 1yr |
| ❌ DON'T BUY | VEEV | Structural de-rating, -38.9% from high |
What Changed vs 2026-03-12
- SYK new breakdown: Not previously at oversold — now RSI 32, death cross confirmed. Medical device selloff broadening.
- LLY approaching capitulation for first time: RSI dropped from 41→30. The GLP-1 moat hasn't changed; the price has.
- JNJ emerging as relative leader: +14.4% 3M stands out against a sea of red. Talc resolution removing overhang.
- MRNA cooling but maintaining trend: +3.1% 30D vs prior +35.9% 30D — the run has plateaued, holding consolidation.
- UNH remains broken: No improvement from prior scan, -44.6% 1yr deepens the destruction.
- TMO continuing to de-rate: -17.8% 3M; life science tools selloff shows no sign of reversal.
Key Discoveries
| Discovery | Implication |
|---|---|
| MDT at RSI 25 | Best entry signal in medical devices in 2+ years — if macro stabilizes, this is a 2-3yr compounder at a real discount |
| LLY first oversold signal | Patient investors who missed the 423% 5yr run may be getting a rare entry window |
| JNJ +14.4% 3M in a broken sector | Talc resolution + diversified pharma/device model = best healthcare risk-adjusted setup right now |
Open Questions
- UNH: Is there a floor at $278, or does CMS rate pressure + ongoing investigations push this toward $220-240?
- Is the life science tools (TMO, IQV, DHR) selloff a 12-month cycle or a 3-5yr structural de-rating from NIH budget cuts?
- VEEV: At -38.9% from high, is the life sciences CRM business model durable enough to warrant consideration at current levels?
Related
10 eventsNo direct external sources are attached to this read.